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Objective: GH replacement therapy in children with GH deficiency (GHD) mainly promotes linear
growth. Not only have very few studies fully analyzed the metabolic consequences of GH therapy, but
also the question as to whether GH may affect adipokine secretion has been insufficiently investigated.
Our aim was to study the effects of GH replacement therapy on auxological data, lipid and glycemic
profiles, insulin homeostasis (HOMA-IR) and serum adipokines in children.
Methods: This was a 1-year prospective study. Thirty-four GHD children (11.6G2.6 years) and thirty
healthy matched controls were enrolled. Children affected by GHD were studied both before beginning
continuous GH replacement therapy and again at 12 months.
Results: At the beginning of the study, total and LDL cholesterol were higher in GHD children than in
controls (P!0.001), whereas HDL cholesterol, triglycerides, insulin, HOMA-IR, leptin, and
adiponectin were similar. At 12 months of continuous GH replacement therapy in the GHD group,
there was a significant increase in both auxological data and IGF-I (P!0.001); total cholesterol
(P!0.001), LDL (P!0.001), triglycerides (P!0.005), and leptin (P!0.001) decreased significantly;
HDL (P!0.003), insulin (P!0.001), HOMA-IR (P!0.001) increased while adiponectin was
unmodified. Furthermore, IGF-ID showed an inverse correlation with leptin D (rZK0.398, PZ0.02).
Conclusions: In GHD children, the evaluation of metabolic parameters proves to be a useful tool for the
evaluation of auxological parameters during GH replacement therapy. In our study, GH replacement
therapy in GHD children improved final height, restored IGF-I levels, reduced leptin levels, and
improved the lipid profile, without producing any unfavorable effects on glucose metabolism.
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The main role of growth hormone (GH) replacement
therapy in children with GH deficiency (GHD) is to
promote linear growth (1). Nevertheless, it is well known
that GH brings about a large number of metabolic effects,
involving lipid and glucose homeostasis, lean and fat
mass (2–5). In adults, GHD influences body composition,
decreases bone mineral density, muscle strength and
cardiac morphology and performance, accelerates
atherosclerosis, promotes an unfavorable lipid and
glucose profile, peripheral insulin resistance, all of
which may lead to higher cardiovascular morbidity
and a poor quality of life (6). It is widely accepted that GH
treatment in adults produces beneficial metabolic effects
(7, 8), while apart from reporting auxological data, in
pediatric patients, only a few studies have fully analyzed
the metabolic consequences of GH replacement therapy.
Moreover, the question as to whether GH may affect
adipokine secretion in children has been insufficientlyn Journal of Endocrinologyinvestigated: leptin and adiponectin are hormones that
are only synthesized and secreted by adipocytes (9); they
are strictly linked to insulin sensitivity status and their
levels depend on body composition (10, 11).
It has been suggested that in children (12), as in adults
(13), GH treatment might bring about a reduction in
leptin probably in relation to fat mass reduction. In young
obese patients affected by the Prader–Willi Syndrome, it
has been established that GH therapy decreases body
mass and leptin concentration while insulin sensitivity
indexes are not significantly influenced (14). It should be
borne in mind that still not enough is known about the
complex interplay between adipokines and GH and the
possible early development of alterations in insulin
sensitivity in GHD children. The aim of this study was to
investigate lipid and glucose profile, insulin homeostasis,
adipokine serum levels in prepubertal GHD children at
baseline and after 12 months of GH replacement therapy
and in age, sex-pubertal status, body mass index (BMI)-
matched controls.DOI: 10.1530/eje.1.02343
Online version via www.eje-online.org
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Patients
Thirty-four prepubertal children, 25 boys and 9 girls,
aged 11.6G2.6 years (range 6.1–15.3 years), affected
by idiopathic isolated GHD and meeting the clinical and
auxological criteria of the GH Research Society (15),
were enrolled in the study. Informed consent was
obtained from parents. GHD was assessed by insulin-
like growth factor-I (IGF-I) levels below the normal
range and low-peak GH response in two dynamic GH
tests (!20 mg/l during GHRHCARG test and!10 mg/l
during insulin tolerance test). We excluded children
with multiple pituitary hormone deficiency in order to
avoid other possible influences on glucose and lipid
metabolism. The patients enrolled had never received
any kind of hormonal replacement therapy or drug.Control group
Thirty healthy subjects, 24 boys and 6 girls, matched for
age, sex-pubertal status, BMI, nutritional behavior, and
geographical area, aged 12.3G2.1 (range 7.9–14.0
years), were recruited as control group. Informed
consent was obtained from parents. GHD was excluded
by normal age-corrected levels of IGF-I. Their growth
velocity and metabolic parameters were studied both at
the beginning of the continuous therapy and then again
at 12 months.Study design
At the beginning of the study, all subjects were
investigated for auxological data (height SDS, weight
SDS, BMI, bone age, chronological/bone age ratio),
serum total IGF-I levels, lipid profile (total cholesterol,
HDL, LDL, triglycerides), glucose metabolism (fasting
glucose and insulin levels), aspartate aminotransferase
(AST), alanine aminotransferase (ALT), leptin, and
adiponectin levels. Insulin resistance was evaluated by
the homeostasis model assessment insulin resistance
index (HOMA-IR), applying the Matthews formula
(fasting serum insulin (mU/ml)!fasting plasma glucose
(mmol/l)/22.5) (16). GHD children received biosyn-
thetic GH (recombinant human GH) once daily at
bedtime with a pen injection system; the initial GH dose
was 25 mcg/kg per day s.c.; during the study, in order to
maintain serum IGF-I levels within the normal range for
sex and chronological age, the cumulative GH dose
administered to all patients was 25 mcg/kg per day for
the first 6 months, 30 mcg/kg per day from months 6 to
9, and finally 35 mcg/kg per day for the last 3 months.
Blood samples for metabolic parameters were taken at
the start of the study and after 12 months both from
GH-treated and healthy children; after centrifugation,
all samples were frozen (K20 8C) until assayed.www.eje-online.orgAnthropometric measurements
Height and weight were expressed in SDS; bone age
delay was evaluated according to Tanner and White-
house (TW2) method (17).Hormone and biochemical assays
Glycemic, AST, ALT and lipid (HDL and total cholesterol,
triglycerides, LDL) levels were measured in our centralized
laboratory with standard methods. Serum GH was
assessed by ELISA method (BioSource hGH-EASIA kit,
Nivelles, Belgium). The sensitivity of the method was
0.07 mg/l. The inter- and intra-assay coefficients of
variation (CV values) were 3.6–4.4 and 3.7–9.8%
respectively, at GH levels of 6.4–21.2 and 1.9–13.1 mg/l
respectively. Serum total IGF-I was assayed in the same
laboratory by ELISA method (OCTEIA IGF-I kit, IDS Inc.,
Fountain Hills, AZ, USA). The sensitivity of the method
was 1.9 mg/l. The inter- and intra-assay CV values were
7–7.1 and 2.3–3.5% respectively, at IGF-I levels of 90.7–
186 and 66.7–120.9 mg/l respectively. The normal
ranges (males and females combined) of total IGF-I levels
(mg/l) were: 12–108 (0–1 years); 13–100 (1–3 years);
26–280 (3–6 years); 85–230 (6–9 years); 98–404 (9–12
years); 142–525 (12–15 years); 146–415 (15–20 years).
Serum leptin levels were measured by ELISA according to
the manufacturer’s instructions (Linco Research, Inc., St
Charles, MO, USA). The sensitivity limit of the assay was
0.5 ng/ml, and the intra- and inter-assay CV values were
2.6–4.6 and 2.6–6.2% respectively, at leptin levels of
2.34–28.9 ng/ml. Serum adiponectin levels were
measured by ELISA according to the manufacturer’s
instructions (Linco Research, Inc.). The sensitivity limit of
the assay was 0.78 ng/ml, and the intra- and inter-assay
CV values were 7.4 and 2.4–8.4% respectively, at
adiponectin levels of 17.73–39.10 ng/ml. Serum insulin
was measured by ELISA (Mercodia Insulin ELISA, Arnika,
Milan, Italy).The sensitivity of the method was 1 mUI/ml.Statistical analysis
We used the SPSS 13 software, Windows Edition, for all
our statistical analyses. Continuous variables were
analyzed as mean valuesGS.D. Rates and proportions
were calculated for categorical data. Differences
between GHD and controls were analyzed by Mann–
Whitney U-test (non-parametric test), as they were
continuous variables without normal distribution. The
differences between paired continuous variables in the
GHD group (before and 1 year after therapy) were
analyzed by the Wilcoxon test. Correlations among
continuous variables without normal distribution were
determined by using the Spearman’s test (non-para-
metric equivalent for Pearson test). For categorical
variables, differences were analyzed by means of the
c2-test and Fisher’s exact test when appropriate.
P!0.05 was considered statistically significant.
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Auxological and metabolic parameters are shown in
Table 1 at baseline (cases and controls) and in Table 2 at
12 months of continuous therapy (only GHD cases). The
patients recruited in our study were all prepubertal and
maintained this status during the first observation period,
i.e., during the first 12 months of GH therapy (Table 3).
Controls did not show any significant differences in
metabolic data and IGF-I levels with respect to baseline
(fasting glycemia: 88.6G5.9 vs 85.3G7.1 mg/dl,
PZ0.055; total cholesterol: 120.5G14.5 vs 127.2G
16.3 mg/dl, PZ0.098; HDL cholesterol: 50.4G11.4 vs
49.2G10.1 mg/dl, PZ0.668; LDL cholesterol: 52.2G
19.7 vs 54.3G17.8 mg/dl, PZ0.668; triglycerides:
89.3G23.8 vs 90.3G21.8 mg/dl, PZ0.869; insulin
levels: 10.7G11 vs 11.3G15.7 mU/ml, PZ0.873;
HOMA-IR: 2.34G2.39 vs 2.39G2.41, PZ0.936; leptin
levels: 5.14G5.03 vs 6.02G5.01 ng/ml, PZ0.499;
adiponectin levels:14.5G8.2 vs 14.3G7.2 ng/ml,
PZ0.960). Auxological parameters (height and weight
SDS) in the control group increased during the first
12 months of the observation period in comparison
with basal evaluation (height SDS: K1.52G0.60 vs
K0.91G0.39, P!0.001; weight SDS:K0.98G0.60 vs
K0.49G0.53, PZ0.001), while there was no significant
increase in IGF-I levels (281.3G132.7 vs 331.6G
123.2 mg/l, PZ0.134).Table 1 Auxological and metabolic data at diagnosis.
Group A (GHD) n
Males: no. (%) 25 (73.52)
Females: no. (%) 9 (26.47)
Auxological data MeanGS.D.
Chronological age 11.60G2.63
Height SDS K2.03G0.64
Weight SDS K1.28G1.08
BMI 17.92G3.90
Bone age 9.84G2.70
Chronological/bone age ratio 1.21G0.18
Familiar height target (cm) 166.51G7.71
IGF-I (mg/l) 79.63G35.5
Metabolic data
Fasting glycemia (mg/dl) 84.23G10.5
Total cholesterol (mg/dl) 163.08G32.6
HDL cholesterol (mg/dl) 47.08G13.6
LDL cholesterol (mg/dl) 96.15G34.3
Triglycerides (mg/dl) 99.20G45.0
ALT (UI/l) 22.47G5.98
AST (UI/l) 16.17G6.41
Insulin levels (mU/ml) 7.50G5.77
Homa-IR 1.58G1.26
Leptin levels (ng/ml) 6.22G8
Adiponectin levels (ng/ml) 14.43G7.27
*Significant values when P!0.05.
aPearson c2.
bMann–Whitney test.At baseline
Auxological data and IGF-I levels. As expected, at the
beginning of the study, height SDS (PZ0.044), bone
age (PZ0.007), and serum IGF-I levels (P!0.001)
were significantly lower in GHD children than in
controls; conversely, chronological/bone age ratio was
significantly higher (P!0.001). No significant
difference was found in BMI (Table 1).
Metabolic data. Significant differences between GHD
children and controls were observed in lipid profiles,
with total cholesterol (163.08G32.67 vs 120.50G
14.53; P!0.001) and LDL cholesterol (95.15G34.32
vs 52.22G19.78; P!0.001) higher in the GHD group
than in controls, although within the normal range.
No differences were found in glycemia (PZ0.206),
insulinemia (PZ0.553), HOMA-IR (PZ0.553), HDL
cholesterol (PZ0.339), triglycerides (PZ0.710), AST
(PZ0.967), ALT (PZ0.815), leptin (PZ0.989), and
adiponectin (PZ0.880).At 12 months of GH therapy
Auxological data and IGF-I levels. In the GHD group,
serum IGF-I levels (P!0.001), height SDS (P!0.001),Z34 Group B (control) nZ30
Pa
24 (80) 0.753
6 (20)
MeanGS.D. Pb
12.32G2.15 0.604
K1.52G0.60 0.044*
K0.98G0.60 0.312
18G2.38 0.730
12.24G2.22 0.007*
1G0.03 !0.001*
168.95G4.63 0.534
1 281.36G132.72 !0.001*
2 88.60G5.91 0.206
7 120.50G14.53 !0.001*
3 50.40G11.45 0.339
2 52.22G19.78 !0.001*
4 89.33G23.81 0.710
22.20G8.12 0.815
15.40G2.01 0.967
10.76G11 0.553
2.34G2.39 0.553
5.14G5.03 0.989
14.49G8.23 0.880
www.eje-online.org
Table 2 Auxological and metabolic data after 12 months of growth hormone (GH) replacement therapy.
GHD nZ34 (at diagnosis) GHD nZ34 (at 12 months)
MeanGS.D. MeanGS.D. Pa
Height SDS K2.03G0.64 K1.62G0.58 !0.001*
Weight SDS K1.28G1.08 K0.97G1.02 !0.001*
BMI 17.92G3.9 18.59G4.05 0.001*
Bone age 9.84G2.70 11.27G2.60 !0.001*
Chronological/bone age ratio 1.21G0.18 1.12G0.08 !0.001*
IGF-I (mg/l) 79.63G35.51 353.85G152.62 !0.001*
Fasting glycemia (mg/dl) 84.23G10.52 86.94G6.18 0.188
Total cholesterol (mg/dl) 163.08G32.67 155.20G34.86 !0.001*
HDL cholesterol (mg/dl) 47.08G13.63 52.73G12.45 0.003*
LDL cholesterol (mg/dl) 96.15G34.32 84.30G34.61 0.001*
Triglycerides (mg/dl) 99.20G45.04 90.82G41.18 0.005*
ALT (UI/l) 22.47G5.98 23.61G8.29 0.639
AST (UI/l) 16.17G6.41 15.61G4.48 0.708
Insulin levels (mU/ml) 7.50G5.77 17.47G11.29 !0.001*
Homa-IR 1.58G1.26 3.73G2.39 !0.001*
Leptin levels (ng/ml) 6.22G8 3.47G5.91 !0.001*
Adiponectin levels (ng/ml) 14.43G7.27 14.98G6.02 0.509
*Significant values when P!0.05.
aWilcoxon test.
Table 3 Pubertal status (Tanner) at baseline and after 12 months of
growth hormone (GH) replacement therapy.
GHD nZ34
(at diagnosis)
GHD nZ34
(at 12 months)
No. (%) No. (%) P
PH status !0.001*
PH1 34 (100) 20 (58.8)
PH2 – 14 (41.2)
PH3 – –
PH4 – –
G status (No. 25 boys) 0.014*
G1 25 (100) 19 (76)
G2 – 6 (24)
G3 – –
G4 – –
B status (No. 9 girls) 0.157
B1 9 (100) 7 (77.8)
B2 – 2 (22.2)
B3 – –
B4 – –
MeanGS.D. MeanGS.D.
FSH (mU/ml) 0.63 (0.34) 0.87 (0.48) !0.001*
LH (mU/ml) 0.35 (0.33) 0.59 (0.40) !0.001*
Total testosterone
(ng/ml; No. 25 boys)
0.25 (0.16) 0.58 (0.43) !0.001*
17b-Estradiol (pg/ml;
No. 9 girls)
4.82 (3.89) 5.54 (4.42) 0.012*
*Significant values when P!0.05 (Wilcoxon test). Normal values of FSH,
LH, total testosterone and 17b-estradiol (prepubertal): FSH: !1.5 mU/ml;
LH!1.7 mU/ml; total testosterone !0.68 ng/ml (boys); 17b-estradiol
!10 pg/ml (girls).
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months of GH therapy with respect to baseline values,
while chronological/bone age ratio (P!0.001) and
weight (P!0.001) decreased (Table 2).
Metabolic data. Total cholesterol (163.08G32.67 vs
155.20G34.86; P!0.001), LDL (95.15G34.32 vs
84.30G34.61; PZ0.001), and triglycerides (99.20G
45.04 vs 90.82G41.18, PZ0.005) showed a signifi-
cative reduction after the first 12 months of therapy,
while a highly significant increase in HDL cholesterol
was observed (47.08G13.63 vs 52.73G12.45,
PZ0.003; Fig. 1). AST (16.17G6.41 vs 15.61G
4.48, PZ0.708) and ALT (22.47G5.98 vs 23.61G
8.29, PZ0.639) after 12 months were similar to
baseline. Insulinemia (7.50G5.77 vs 17.47G11.29)
and HOMA-IR (1.58G1.26 vs 3.73G2.39) increased
when compared with baseline values (P!0.001), while
glycemia was unmodified (84.23G10.52 vs 86.94G
6.18, PZ0.188). Leptin values significantly decreased
(6.22G8 vs 3.47G5.91, P!0.001) after replacement
therapy, while adiponectin (14.43G7.27 vs 14.98G
6.02, PZ0.509) remained unmodified in all GH-treated
children (Fig. 2). Considering IGF-I as the main marker
of successful therapy, we examined the possible
correlations between IGF-I and all metabolic parameters
both at baseline and after 12 months of GH therapy. In
addition, we calculated D values (0–12 months) of total,
HDL and LDL cholesterol, triglycerides, insulinemia,
HOMA-IR, leptin, and adiponectin and analyzed their
correlation with IGF-ID, resulting in a significant
inverse correlation between leptin D and IGF-ID
(rZK0.398; PZ0.02; Fig. 3).www.eje-online.orgDiscussion
In the present study, baseline leptin and adiponectin
concentrations were identical in GHD and healthy
children. A significant decrease in leptin levels was
found at 1 year of continuous GH treatment without
any change in adiponectin. Insulin sensitivity was only
slightly influenced by GH therapy with an increase in
HOMA-IR, related to increased insulin levels without
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Figure 1 Lipid profile before and after 12 months of GH replacement therapy in GHD patients.
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Figure 2 Leptin and adiponectin before and after 12 months of GH
replacement therapy in GHD patients.
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by GH therapy as in adults with GHD.
GH has both insulin-like (IGF-I dependent) and anti-
insulin-like effects on cells and tissues. GH reduces body∆-
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Figure 3 DIGF-I/D-leptin correlation.
www.eje-online.orgfat involving both decreased lipogenesis and increased
lipolysis. For this reason, GHD in adult life is associated
with alterations in body composition (increased central
adiposity, deficit in lean mass, and osteopenia),
decreased peripheral insulin sensitivity with modest
fasting hyperinsulinemia, abnormal glucose tolerance,
higher total and LDL cholesterol levels and a variable
prevalence of hypertriglyceridemia, premature athero-
sclerosis and increased risk of cardiovascular disease
(6). GH replacement therapy in adults has beneficial
effects on all these parameters (18).
It is interesting to note that in GHD adolescents who
discontinue GH treatment at completion of linear
growth, there are unfavorable effects on body compo-
sition, glucose and lipid profiles, bone mineral density,
and cardiac function (19–21). Lanes et al. (5) report
increased LDL cholesterol levels in GHD adolescents
when compared with healthy controls, whereas total
HDL cholesterol and triglyceride concentrations were
similar in the two groups; conversely, other authors
have not reported any abnormalities in lipid profiles
(22–24). In our study, at baseline, we found a
significant difference in total and LDL cholesterol
between GHD children and controls, with significantly
higher levels in the first group, though still within the
normal range. Kuromaru et al. reported a decrease in fat
mass, LDL and total cholesterol, and an increase in lean
mass and HDL cholesterol after 6 months of GH
treatment (2). Our study also confirms improvement
in lipid profile after 12 months of GH replacement
therapy compared with baseline, with a significant
reduction in total cholesterol, LDL, and triglyceride
levels and a concomitant slight rise in HDL.
As several studies have reported, GH plays an
important role in glucose and insulin metabolism.
Some authors have found a degree of insulin resistance
in untreated GHD adults and increased peripheral
insulin sensitivity after GH therapy (7, 8); while others
have not found any difference in glycemia, insulinemia,
and HOMA-IR between untreated GHD adults and
control subjects, or any variation after GH therapy (25).
In pediatric patients, the effect of GH therapy on serum
insulin levels has also been reported (26), showing a
trend towards reduced insulin sensitivity with a
compensatory hyperinsulinemic response. Saenger
(27) reported a slight increase in insulin levels in a
group of GHD children after 36 months of GH therapy,
with normal glucose levels. Conversely, some authors
have reported increased incidence of diabetes mellitus or
impaired glucose tolerance in children and adolescents
receiving GH treatment (28). In our study, we did not
observe any significant difference between GHD patients
and healthy subjects on baseline glycemic and insuli-
nemic levels while after 12 months of GH replacement
therapy we found an increase in insulin levels and
HOMA-IR without any untoward effects on glucose
metabolism. We hypothesize that the increase in
HOMA-IR, due to the relative hyperinsulinemia, mainly
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does not reflect a real status of insulin-resistance, as
suggested by the adiponectin levels. These levels, in
fact, which are recognized as inversely related to
insulin resistance (10), did not change during the first
year of continuous therapy. In addition, the increase in
insulin levels observed after GH treatment may be
consistent with the absence of the inhibitory feedback
of the leptin on insulin synthesis and release (adipo–
insular axis) (29).
GH therapy has been shown to reduce serum leptin,
but the complex interplay of the GH/IGF-I axis in the
modulation of leptin levels is still not fully understood.
Several studies have reported the effects of GH on
adipokines in adult GHD (13). Matsuoka et al. (30) also
observed changes in body composition and in leptin
levels during the first year of GH therapy in short
children without GHD. Our findings have shown that
after 12 months of treatment, a significant decrease in
leptin levels can be observed in GHD children; this effect
may be related to body fat reduction, which is the
predominant metabolic effect of therapy. Although it is
by now generally accepted that during puberty both
healthy and GHD females have higher leptin levels, we
did not find any gender-related differences, probably
because we enrolled only prepubertal subjects.
Moreover, the change in leptin levels observed during
the 12 months of GH replacement therapy was inversely
correlated with the change in IGF-I levels; in our study,
therefore, leptin levels proved to be an adjunctive tool in
metabolic evaluation during GH therapy (Fig. 3).Table 4 Correlation between D TT/D E2 and D metabolic data.
r of Spearman DTT DE2
D Total cholesterol Correlation coefficient K0.291 0.427
P 0.158 0.252
No cases 25 9
D HDL cholesterol Correlation coefficient 0.170 0.172
P 0.417 0.658
No cases 25 9
D LDL cholesterol Correlation coefficient K0.299 0.209
P 0.146 0.589
No cases 25 9
D Triglycerides Correlation coefficient K0.169 K0.099
P 0.419 0.799
No cases 25 9
D Insulin Correlation coefficient 0.245 K0.510
P 0.239 0.160
No cases 25 9
D Homa-IR Correlation coefficient 0.218 K0.393
P 0.294 0.295
No cases 25 9
D Leptin Correlation coefficient K0.169 0.510
P 0.419 0.160
No cases 25 9
D Adiponectin Correlation coefficient 0.309 K0.017
P 0.133 0.966
No cases 25 9
r of Spearman correlation. Significant values when P!0.05.In addition, in our prepubertal patients, the minimal
physiological modifications in gonadotropin levels did
not seem to influence the metabolic parameters
examined, as demonstrated by the absence of a
significant correlation between D in gonadotropin and
sex hormones (total testosterone for boys and 17b-E2
for girls) and D in each metabolic parameter is
examined (Table 4).
In conclusion, the results of this prospective study
demonstrate that continuous GH replacement therapy
in GHD children shows, at 12 months, an improvement
in final height, restores IGF-I levels, reduces leptin levels
and improves the lipid profile, without producing any
unfavorable effects on glucose metabolism.References
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